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Fig. 5. Stochastic resonance effects. (A)Maximumof the power spectrumpeakof the signal given by differences between the level of synchronization between
both communities versus the noise level (variance). (B) Maximum in the power spectrum of the signal given by differences between the level of synchronization
between both communities versus the noise level. (C) Correlation between the level of synchronization between both communities versus the noise level. Note
the stochastic resonance effect that for the same level of fluctuations reveals the optimal emergence of 0.1-Hz global slow oscillations and the emergence of
anticorrelated spatiotemporal patterns for both communities. Points (diamonds) correspond to numerical simulations, whereas the line corresponds to a
nonlinear least-squared fitting using an -function.
www.pnas.org/cgi/doi/10.1073/pnas.0906701106
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A large body of evidence strongly suggests that the p53 tumor
suppressor pathway is central in reducing cancer frequency in verte-
brates. The protein product of the haploinsufficient mouse double
minute 2 (MDM2) oncogene binds to and inhibits the p53 protein.
Recent studies of human genetic variants in p53 and MDM2 have
shown that single nucleotide polymorphisms (SNPs) can affect p53
signaling, confer cancer risk, and suggest that the pathway is under
evolutionary selective pressure (1–4). In this report, we analyze the
haplotype structure of MDM4, a structural homolog of MDM2, in
several different human populations. Unusual patterns of linkage
disequilibrium (LD) in the haplotype distribution of MDM4 indicate
the presence of candidate SNPs that may also modify the efficacy of
the p53 pathway. Association studies in 5 different patient popula-
tions reveal that these SNPs in MDM4 confer an increased risk for, or
early onset of, human breast and ovarian cancers in Ashkenazi Jewish
and European cohorts, respectively. This report not only implicates
MDM4 as a key regulator of tumorigenesis in the human breast and
ovary, but also exploits for the first time evolutionary driven linkage
disequilibrium as a means to select SNPs of p53 pathway genes that
might be clinically relevant.
evolutionary selection pressure  linkage disequilibrium  p53 pathway 
tumorigenesis  single nucleotide polymorphisms
Thep53 signaling pathwaymediates a cellular stress response thatis activated on stresses such as DNA damage and oncogene
activation. This signaling pathway initiates cellular responses such
as DNA repair, cell cycle arrest, cell death (apoptosis), and senes-
cence (5) and has been demonstrated to be crucial both in reducing
cancer frequency in vertebrates and in mediating the response of
commonly used cancer therapies (6–8). The protein product of the
mouse double minute 2 (MDM2) oncogene binds to, and inhibits,
the p53 protein (9). It has been shown in multiple mouse models
that even a modest change in the expression level can affect
p53-dependent tumor suppression in mice (10, 11). It was reasoned
that such observations allow for the possibility that changing just a
few (or even just one) base pair(s) in regulatory regions of the
gene could alter the levels ofMDM2 activity enough to affect the
p53 pathway and, therefore, cancer in humans (1). Extensive
study of a single nucleotide polymorphism (SNP) in the pro-
moter of MDM2 (MDM2 SNP309, rs2279744, T/G) has lent
support to this hypothesis (1–3).
The MDM2 SNP309 locus results in either a thymine (T) or
a guanine (G) in the intronic promoter/enhancer region of the
MDM2 oncogene (1). The G-allele of MDM2 SNP309 was
shown to increase the affinity of the transcription factor Sp1,
which resulted in the increased transcription and expression of
the MDM2 protein (1). In concordance to these initial obser-
vations, the G-allele of MDM2 SNP309 has been shown to
associate with significantly higher levels of MDM2 expression in
tumor-derived cell lines (1, 12, 13), in renal cell carcinoma (14),
in normal esophageal tissue (15), and in B-cell chronic lympho-
cytic leukemia (16). In tumor-derived cell lines, the elevated
levels of MDM2 associated with the G-allele have been shown
in multiple studies to result in the attenuation of the p53
apoptotic response after exposure to multiple types of chemo-
therapeutic agents, compared with cells containing the T-allele
(1, 12, 17). It was proposed that the high levels of MDM2
resulting from the G-allele attenuate the p53 stress response,
resulting in a higher mutation rate, poorer DNA repair pro-
cesses, reduced apoptosis, and senescence, leading to faster and
more frequent tumor formation (1). Support for the model has
come from the association of MDM2 SNP309 with differences
in the onset of, or the risk for, cancer, as well as survival (2, 3,
18). For example, earlier ages of onset associated with individ-
uals possessing the G-allele have been demonstrated in soft-
tissue sarcomas (1, 19, 20), lymphoma (21), leukemia (22),
melanoma (23), head, neck, and oral squamous cell carcinomas
(24, 25), and cancers of the colon (26), breast (21, 27, 28),
bladder (29), ovary (30), brain (31), and liver (32).
Recently, the MDM2 haplotype structure was determined in
humans from several different demographic groups (33). It was
noted that the frequency of the haplotype harboring the functional
G-allele ofMDM2SNP309deviated significantly from the standard
assumptions of models of selective neutrality by using multiple
selection tests, including an entropy-based selection test that com-
pares both the frequency and long-range correlations of an allele
with a simulated neutral model, where the allele is selectively
neutral. These observations suggested that the human p53 pathway
could be acted on by an evolutionary selection pressure. Indeed, it
had been previously and subsequently shown that a well-regulated
p53 pathway is crucial for proper murine embryonic development,
embryonic implantation, pregnancy rates, and litter sizes (33, 34),
and also human embryonic implantation (35). Thus, the p53
pathway not only plays a role in genomic error correction in the
lifetime of humans, but also determines the fate of viable genetic
transmissionon the timescale of generations. From this observation,we
reasoned that other SNPs in the p53 pathwaywith signatures of natural
selection might also alter cancer risk in humans.
To this end, we chose to focus on the haplotype structure of
MDM4, a structural homolog of MDM2 and a key inhibitor of p53
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(36–38), in the hope of detecting functional genetic variants that
alter p53 pathway activity and, ultimately, are associated with risk
of human tumorigenesis. Like MDM2, its structural homolog,
MDM4, can also bind directly to p53 and inhibit its ability to
function as a transcriptional activator, aswell as regulate its stability,
most likely through its interactions withMDM2 (37, 38). Its central
role in regulating p53 activity and human cancer has been high-
lighted by many observations. For example, MDM4 is an essential
gene in murine development, and knockout embryos die in utero.
This lethal phenotype can be rescued by knocking out the p53 gene
(36). In human cancer, MDM4 was found to be amplified or
over-expressed in a large subset of human tumors (38–40). Terzian
et al. recently demonstrated that similar to Mdm2, Mdm4 haplo-
insufficiency leads to increased p53 activity exhibited as increased
sensitivity to DNA damage, decreased transformation potential,
and tumor development (41). These data suggest that changing just
a few (or even just one) base pair(s) inMDM4 could alter the levels
of MDM4 enough to affect the p53 pathway and, therefore, cancer
in humans. In this report, data are presented that both support this
hypothesis as well as implicate MDM4 as a key regulator of
tumorigenesis in human breast and ovary.
Results
Genotype data for SNPs across MDM4 were collected from 3
sources: (i) a collection of 84 lymphoblastoid cell lines from the
Coriell Institute for Medical Research Diversity Cell line panel (46
from African Americans and 38 from Caucasians), of which 10
SNPs were chosen to characterize the haplotype diversity across the
largest isoform of the transcript (Fig. 1A); (ii) the Caucasian (CEU)
and African (Yoruba, YRI) populations of the International Hap-
Map project, of which 46 SNPs were selected across the gene
including those lying 10 kb 5 of the first exon and 10 kb 3 of the
terminal exon; and (iii) a cohort of 299 Caucasian females of
Ashkenazi Jewish (AJ) ancestry (see Materials and Methods), of
which 13 SNPs mapping within and immediately surrounding the
MDM4 gene were selected (Fig. 2A).
After the genotypes were computationally phased into haplo-
types (42), we began determining the linkage patterns of SNPs as
quantified by the pair-wise correlation statistics D and r2 (see Fig.
1 B and C for Coriell Caucasians and African Americans and Fig.
2B for AJ Caucasians). We noted that many SNPs are tightly
correlated along the extent of the gene, more so in the Caucasian
population than in the African and African American datasets (see
Fig. 1. Haplotype structures of the MDM4 oncogene in a Caucasian and in an African American population. (A) A schematic diagram of the MDM4 gene and
the SNPs genotyped in the present study. Pairwise linkage disequilibriums are shown for the Caucasian (B), and the African American (C) populations. The upper
right triangles report the Dmeasures, and the lower left triangles report the r2 measures. The inferred haplotype frequencies in the Caucasian (D) and African
American (E) populations centered around a particular SNP (SNP-6, rs2369244; denoted with a red box in A), where G(C) is the ancestral (derived) allele.






Fig. 1B vs. 1C for the linkage patterns in the Coriell datasets and
Figs. 2B and Fig. S1 in AJ), most likely because of the reduced
number of recombination events in the genealogical history of the
Caucasian population. The common haplotypes in the Caucasian
population, from the Coriell dataset and the Hapmap dataset,
exhibit similar frequencies to those in the AJ population (Figs. 1D
and 2C). Analysis of the marginal haplotypes of the 10 SNPs in the
Coriell dataset revealed that there is a dominant haplotype in 67%
of the Caucasian population, and the same haplotype (Fig. 1D),
when extended to the 46 SNPs of the public Hapmap dataset,
constitutes 50% of the CEU population. The African American
dataset from Coriell and the YRI dataset from Hapmap also
include this haplotype, but at lower frequencies (Fig. 1E). The
marginal haplotype frequencies from the Coriell dataset inferred
from this calculation are shown in Fig. 1 D and E, centered around
a particular SNP (SNP-6, rs2369244), where G(C) is the ancestral
(derived) allele. The high frequency and large extent of the derived
haplotype and the low diversity in all of the populations suggest the
possibility that the derived haplotype could have arisen because of
natural selection.
To test the possibility of natural selection, we applied a battery
of classical tests of neutrality (Fu and Li’s F, Fu and Li’s D, Tajima’s
D) that implicitly invoke different assumptions about the expected
frequency distribution of alleles across a set of neutral SNPs.
However, these tests suffer from 3 main deficits: (i) they ignore
multiallelic correlations and thereby reduce their power to detect a
recent reduction in haplotype diversity, i.e., selective sweep; (ii)
historical episodes of reduced population sizes (population bottle-
necks) can give rise to a distribution of allele frequencies that
appear to be nonneutral; and (iii) these classical tests do not
explicitly pinpoint which allele or haplotype is under selection
pressure. In an attempt to overcome these deficits, we also per-
formed a previously described selection test for each SNP, based on
the entropy of the marginal haplotype distributions (33). Interest-
ingly, the entropy-haplotype selection tests and the majority of the
classical selection tests suggest a significant departure from neu-
trality of theMDM4oncogene in theCaucasian,AfricanAmerican,
and Ashkenazi-Jewish populations (Table 1). In particular, the
entropy-haplotype test rejects the null hypothesis of neutrality for
several tightly linked SNPs using the conventional significance
threshold of 0.05, adjusted with the conservative Bonferroni cor-
rection for multiple hypotheses testing. In Figs. 1D, 1E, and 2C, we
present the marginal haplotypes associated with one of these
selected SNPs (i.e., SNP-6, rs2369244). The evidence for selection
in the Yoruba population from the Hapmap seems less compelling
than the others, and the Yoruba is the only population that is not
significant under the entropy-haplotype test.
Fig. 2. Haplotype structure of the MDM4 oncogene in a Caucasian population of AJ ethnicity. (A) A schematic diagram of the MDM4 gene and the SNPs
genotyped in the present study. (B) Pairwise linkage disequilibriums for the Caucasian population of AJ ethnicity. The upper right triangles report the D
measures, and the lower left triangles report the r2 measures. (C) The inferred haplotype frequencies in the population centered on a particular SNP (SNP-9,
rs2369244; denoted with a red box in A), where G(C) is the ancestral (derived) allele.
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The above-described analysis suggests that the genetic variants in
the MDM4 oncogene have undergone a selective sweep. As this
scenario is similar to the haplotype containing the functional
SNP309 in the MDM2 oncogene (33), it was hypothesized that the
MDM4 haplotype distribution might also harbor one or more
functional SNPs and therefore also demonstrate allelic differences
in human cancer populations. To test this hypothesis, a set of SNPs
was used, each of which can differentiate the nonneutral major
MDM4-haplotype (the major alleles) from the other neutral
MDM4 haplotypes, and it was determined whether their genotypes
were associated with either altered cancer risk in case/control
studies for familial and sporadic breast cancer or age-dependent
incidence in case studies for both familial and sporadic ovarian
cancers.
Functional p53 pathway polymorphisms and somatic genetic
alterations of p53 pathway genes have been shown to affect breast
cancer incidence, progression, and/or survival (2, 43, 44). There-
fore, we sought allelic differences in cancer risk for the MDM4
haplotype, first by using data generated in a 2-stage genome-wide
association study (GWAS) performed on anAffymetrix 500K (Affy
500K) platform that has identified breast cancer susceptibility loci
in the AJ population (45). We used the data that originated from
the first stage of the GWAS that was carried out in 250 AJ
Caucasian women affected with breast cancer, with a family history
of 3 or more breast cancers in a single lineage, and who tested
negative for the 3AJ breast cancer (BRCA) foundermutations, and
300 healthy AJ controls. We then sought confirmation of noted
allelic differences in an additional dataset that originated from an
unpublished GWAS, constituted of a cohort of 240 sporadic breast
cancer patients unselected for family history orBRCA1/2 status and
also genotyped by using an Affy 500K array. Among the SNPs that
differentiated the nonneutral, major MDM4-haplotype from the
other MDM4 haplotypes, 3 MDM4 SNPs were also present on the
array and genotyped with good quality [in Fig. 2A: SNP-1
(rs10900594), SNP-9 (rs2369244), SNP-12 (rs12039454)]. Similarly
to the above-described analysis, all 3 SNPs were in high LD (D 
0.9) in the AJ controls and patients (Fig. S1). Interestingly, statis-
tically significant allelic associations for all 3 loci in both groups
(familial and sporadic breast cancer cohorts) of patients were
observed when compared with the 300 AJ controls (Fig. S1). The
distributions of the genotypes for all 3 SNPs varied significantly
between the cases and controls as indicated in Table 2. For all 3
SNPs, these differences resulted in an enrichment of the minor
allele homozygotes in the cases and the subsequent decrease of the
major allele homozygotes (Table 2 and Table S1).
We then sought to confirm these observations by genotyping
SNP-9 (rs2369244) in another, independent cohort of 654AJ breast
cancer cases and 1,085 AJ controls. Similar to the findings in the
GWAS cohorts, the minor allele homozygotes were significantly
enriched in the cases compared with the controls (P  0.01, Table
S1). Furthermore, a meta-analysis of all 3 cohorts, controlling for
age, suggests that a SNP, which can differentiate the nonneutral,
majorMDM4 haplotype from the other neutralMDM4 haplotypes
(SNP-9, rs2369244) demonstrates significant associations with al-
tered AJ breast cancer risk (Table 3). Specifically, the minor allele
homozygotes (G/G), representing the neutral MDM4 haplotypes,
associate with an increased breast cancer risk with an OR of 1.52
(95% CI 1.18–1.95, P 0.00085) and C/G with an OR of 1.2 (95%
CI 1.01–1.42, P  0.037). It is important to note that similar
associations were sought in non-AJ Caucasian breast cancer studies
(46) (Table S2) and not observed, suggesting potential ethnic
differences in these results.
Table 1. Results of various selection tests
Selection test Coriell, Caucasian
Coriell, African
American Hapmap,CEU Hapmap,YRI MSKCC,AJ
Fu and Li’s F 0.05  P  0.1 0.05  P  0.1 0.05  P  0.1 P  0.02 0.05  P  0.1
Fu and Li’s D P  0.02 P  0.02 P  0.02 P  0.05 P  0.02
Tajima’s D P  0.01 P  0.01 P  0.01 P  0.1 P  0.01
Entropy haplotype P  0.02 P  0.05 P  0.05 0.05  P  0.1 P  0.01
Table 2. Significant enrichments of the minor allele homozygotes suggest increased familial and sporadic breast cancer risk
Study SNP Genotype
Number Percent
Odds ratio 95% CI* P value†Controls Cases Controls Cases
Familial breast cancer rs10900594 GG 134 94 45 39 1
CG 140 108 47 45
CC 23 36 8 15 2.2 1.24–4.01 0.0065
rs2369244 CC 130 95 44 39 1
CG 144 114 48 47
GG 24 36 8 15 2.1 1.15–3.67 0.01408
rs12039454 CC 133 95 44 38 1
CT 143 114 48 46
TT 23 39 8 16 2.4 1.3–4.2 0.00294
Sporadic breast cancer rs10900594 GG 126 83 47 35 1
CG 119 119 45 50
CC 21 35 8 15 2.5 1.38–4.65 0.00231
rs2369244 CC 121 80 45 34 1
CG 123 117 46 50
GG 22 37 8 16 2.5 1.40–4.63 0.00187
rs12039454 CC 124 82 46 34 1
CT 122 119 46 50
TT 21 37 8 16 2.7 1.46–4.88 0.00118
*Using the approximation of Woolf .
†Two-sided Fisher’s Exact Test.






Together, the results of the AJ familial and both AJ sporadic
breast cancer studies significantly support the hypothesis that
MDM4 haplotypes might also harbor functional SNP(s), as in all 3
studies the minor allele homozygotes of SNPs that can differentiate
the neutral from the nonneutral haplotypes were enriched in those
with cancer compared with controls. However, to further test the
hypothesis, allelic differences for the MDM4 haplotype were ex-
plored in a different tumor type and by using a different experi-
mental design. As functional p53 pathway polymorphisms and
somatic genetic alterations of p53 pathway genes have also been
shown to affect ovarian cancer (30, 43, 44), potential allelic differ-
ences in the age of diagnosis were tested in case studies of both
familial and sporadic ovarian cancer in Caucasian populations of
non-AJ ethnicity.
The first ovarian cancer case study consists of 244 individuals that
are members of families with extremely high rates of breast and
ovarian cancer. In this cohort, 95 women have been diagnosed with
ovarian cancer and were genotyped for a MDM4 SNP that can
differentiate the nonneutral, major MDM4-haplotype from the
other MDM4 haplotypes in the Caucasian population (SNP-7,
rs1563828; seeFig. 1A,B, andD). Interestingly, there are significant
allelic differences in the age of diagnosis between the genotypes. In
this population, the median age of diagnosis was very young at 52
years of age. However, the women homozygous for the major allele
were diagnosed on average at 56 years of age, with those heterozy-
gous or homozygous for the minor allele diagnosed on average
either 4 or 5 years earlier, respectively (P 0.0236, Mann–Whitney
Test) (Fig. 3A).
To confirm and extend these observations, this same SNP was
analyzed in a second, independent case study of 110 individuals
diagnosed with invasive ovarian carcinomas. As expected, this
sporadic population was diagnosed on average much later than the
familial cohort, with a median age of diagnosis of 64 years (P 
0.0001, unpaired t test). Interestingly, the minor allele homozygotes
were also diagnosed 9 years earlier than the major allele homozy-
gotes (P 0.0137, Mann–Whitney) (Fig. 3B). Together, these data
provide evidence that genetic variants in MDM4 can affect tumor
suppression in familial and sporadic ovarian cancers, whereby the
minor allele carriers associate with the development of tumors
earlier in life.
Discussion
In summary, we have first shown that the human MDM4 gene
harbors a haplotype that deviates from standard assumptions of
selective neutrality, using a variety of selection tests, in 3
different populations of Caucasians of different ethnic back-
grounds and in 1 population of African Americans. Secondly, we
have demonstrated that the minor allele homozygotes, and
therefore the neutral haplotypes, are associated with both a
greater risk of developing breast tumors in 3 independent AJ
case cohorts and developing ovarian tumors up to 9 years earlier
in life, in both familial and sporadic ovarian cancer in non-AJ
Caucasian cohorts. These data support the initial hypothesis that
haploinsufficient MDM4, like haploinsufficient MDM2, harbors
a genetic variant that affects human cancer. With what is known
of MDM4 function to date, it is tempting to speculate that a
SNP(s) associated with this haplotype would result in allelic
differences in MDM4 activity levels. In turn, the differences in
MDM4 activity levels would result in differences in the p53 stress
response, resulting in a higher mutation rate, poorer DNA repair
processes, reduced cell cycle arrest, apoptosis, and senescence
leading to faster and more frequent tumor formation (Fig. S2).
As mentioned in the introduction, it was previously shown that
the nonneutral haplotype of the MDM2 oncogene harbors the
G-allele of MDM2 SNP309 and associates with an attenuation of
the p53 pathway, altered MDM2 expression, and enhanced early
onset of, or increased risk for, tumorigenesis (33). In this report,
we demonstrate that in the case of the MDM4 oncogene, it is the
neutral haplotype that associates with increased breast cancer
risk and an earlier age of onset of ovarian cancer, which could
suggest a weaker p53 pathway. In both cases, the deviations that
form the standard assumptions of selective neutrality are more
readily explained by models of positive selection. This observa-
tion could suggest that both a weaker and stronger p53 pathway
could be under positive selection pressure. Interestingly, both
toomuch p53 activity, as well as too little, has been demonstrated
Table 3. AJ meta-analysis
rs2369244 Cases Controls OR (95% CI)
P value,
chi square
CC 404 (35) 557 (41) 1
CG 549 (48) 631 (47) 1.2 (1.01–1.42) 0.037
GG 180 (16) 163 (12) 1.52 (1.18–1.95) 0.00085
Total 1,133 1,351
Fig. 3. A tagSNP that differentiates the nonneutral MDM4-haplotype from the neutral haplotypes demonstrates significant allelic differences in the age of
diagnosis of both familial and sporadic ovarian cancer. The cumulative incidence of ovarian cancer for both the women T/T in genotype (black triangles) and
C/C in genotype (gray diamonds) for rs1563828 is plotted as a functionof age for familial (A) and sporadic (B) disease. Thep-values onbothpanelswere calculated
by comparing the medians of both genotypes by using a Mann–Whitney Test.
10240  www.pnas.orgcgidoi10.1073pnas.0901298106 Atwal et al.
to be correlated with reduced fecundity in mice and could help
explain these observations. For example, in a recent report,
significant decreases in embryonic implantation, pregnancy rate,
and litter size were observed in matings with p53-null female
mice, but not with p53-null male mice, suggesting that the
absence of p53 in the mother is deleterious toward successful
mating (34). In contrast, multiple studies have shown that the
absence of the key negative regulators of p53, MDM2 and
MDM4, in embryos results in early embryonic lethality, which is
rescued by knocking out the p53 gene (8, 36). These data suggest
that too much p53 activity in the embryo is deleterious for
successful embryonic development. Hence, more p53 activity in
mothers could be advantageous for successful propagation and
therefore selected, whereas less p53 activity in embryos could be
advantageous and therefore selected.
Of course, the observations reported here remain to be
validated in other patient cohorts, and it will be important to
determine the precise regulatory changes associated with the
MDM4 SNP(s) and their effect on MDM4 activity and p53
signaling. However, these data strongly suggest thatMDM4 plays
a significant regulatory role in the development of breast and
ovarian cancers and that theMdm4 gene harbors genetic variants
that can affect human cancer and may be under evolutionary
selection pressure. Lastly, these data also suggest that evolu-
tionary driven linkage disequilibrium can be used as a means to
select SNPs of p53 pathway genes that might be clinically
relevant.
Methods
Haplotype and Selection Analysis. A description of the populations and geno-
typing can be found in SI Methods.
Selection test. The entropy selection testwas previously described in detail (33),
and a brief description can be found in SI Methods.
AJ Breast Cancer Cases and Controls. Populations. The case and control popu-
lations studied in the GWAS portion of this studywere described previously in
detail (45), and a brief description can be found in SI Methods.
Familial and Sporadic Ovarian Cancer. Familial ovarian cancer population. Breast
and ovarian cancer families were identified through the Padua Hereditary
Breast/Ovarian Cancer Center of the Istituto OncologicoVeneto (Padova, It-
aly). Family selectionwas based on published operational criteria (47). Ninety-
five of the 131 affected probands were diagnosed with ovarian cancer.
Among them, 33 were carriers of BRCA1 (26 patients) or BRCA2 (7 patients)
germline pathogenic mutations. Blood samples were obtained from each
proband or family member after informed consent as to the aims of the
research project. The study was performed in accordance with the principles
embodied in the Declaration of Helsinki and was approved by the Oncology
Centre Ethical and Technical Scientific Committees.
Sporadic ovarian cancer population. This patient population was previously de-
scribed in great detail (30), and a brief description can be found in SI Methods.
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